Sign in

    Christopher Anzalone

    President, Chief Executive Officer, and Director at Arrowhead Pharmaceuticals Inc
    Board
    Since December 1, 2007
    Age
    55 years
    Education
    Earned a Ph.D. in Biology from UCLA and a B.A. in Government from Lawrence University.
    Tenure
    Joined ARWR on December 1, 2007 and has served as President, Chief Executive Officer, and Director since then.

    Also at Arrowhead Pharmaceuticals Inc

    JH
    James Hamilton
    Chief of Discovery and Translational Medicine
    KAM
    Kenneth A. Myszkowski
    Chief Financial Officer
    PCO
    Patrick C. OBrien
    Chief Operating Officer and General Counsel

    About

    Christopher Anzalone is 55 years old and has built a career marked by significant accomplishments in biotechnology leadership. He earned his Ph.D. in Biology from UCLA and his B.A. in Government from Lawrence University, establishing a strong academic foundation for his future endeavors.

    Since December 1, 2007, he has served as President, Chief Executive Officer, and Director at ARWR, guiding the company through various phases of business and technical development. His leadership has been instrumental in shaping strategic partnerships and advancing the company's innovative pipeline in the biotechnology sector.

    Prior to his tenure at ARWR, he held key roles in the private equity and biotechnology fields, including founding the Benet Group LLC and serving as a partner at Galway Partners, LLC. His diverse professional background underscores a deep commitment to fostering innovation and driving business growth within the sector.

    $ARWR Performance Under Christopher Anzalone

    Past Roles

    Organization Role Date Range Details
    The Benet Group LLC Founder and Chief Executive Officer Prior to December 1, 2007 A private equity firm focused on creating and building new nano-biotechnology companies from university-generated science
    Galway Partners, LLC Partner 1999 to 2003 A Washington, DC-based private equity firm involved in sourcing, structuring, and building new business ventures

    Fixed Compensation

    Data from  FY 2024
    Component NameAmountPayment ScheduleAdditional Details
    Salary$951,012 N/AFiscal year 2024
    Non-Equity Incentive Plan Compensation$1,152,000 N/AFiscal year 2024
    All Other Compensation$1,461 N/AIncludes 401(k) matching contributions and life insurance premiums

    Performance Compensation

    Data from  FY 2024

    Grant Details

    MetricValueAdditional Details
    Grant DateDecember 22, 2023 N/A
    Grant TypePerformance-based Restricted Stock Units (PRSUs) N/A
    Grant Date Fair Value$10,319,000 N/A
    Number of Shares Granted340,000 PRSUs N/A

    Vesting and Performance

    MetricValueAdditional Details
    Vesting ConditionSpecific performance condition Determined to be 100% probable as of the grant date
    Vesting ScheduleNot explicitly detailed N/A
    Performance MetricsNot providedDetailed thresholds, targets, weights not provided